Friday, November 30, 2018

ViaCyte Raises $80M In Series D Funding

San Diego-based biotech startup ViaCyte, which is developing human cell therapy for treating diabetes, says it has raised $80M in a Series D funding round. The funding was led by Bain Capital Life Sciences, and also included TPG, RA Capital Management, Sanderling Ventures, plus angels. According to the company, the funding will go to advance its stem cel

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---